Scinai Immunotherapeutics Statistics Share Statistics Scinai Immunotherapeutics has 853K
shares outstanding. The number of shares has increased by 1.89%
in one year.
Shares Outstanding 853K Shares Change (YoY) 1.89% Shares Change (QoQ) 0.02% Owned by Institutions (%) n/a Shares Floating 833.81K Failed to Deliver (FTD) Shares 34,369 FTD / Avg. Volume 2.55%
Short Selling Information The latest short interest is 28.37K, so 3.04% of the outstanding
shares have been sold short.
Short Interest 28.37K Short % of Shares Out 3.04% Short % of Float 10% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 0.56 and the forward
PE ratio is null.
Scinai Immunotherapeutics's PEG ratio is
-0.01.
PE Ratio 0.56 Forward PE n/a PS Ratio 4.11 Forward PS n/a PB Ratio 0 P/FCF Ratio 0 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Scinai Immunotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position Current Ratio 0 Quick Ratio 0 Debt / Equity 0 Debt / EBITDA 2.61 Debt / FCF -2.05 Interest Coverage -6
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $21.23K Profits Per Employee $154.71K Employee Count 31 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -60.37% in the
last 52 weeks. The beta is 1.86, so Scinai Immunotherapeutics's
price volatility has been higher than the market average.
Beta 1.86 52-Week Price Change -60.37% 50-Day Moving Average 2.21 200-Day Moving Average 2.93 Relative Strength Index (RSI) 30.04 Average Volume (20 Days) 1,348,983
Income Statement In the last 12 months, Scinai Immunotherapeutics had revenue of 658K
and earned 4.8M
in profits. Earnings per share was 5.95.
Revenue 658K Gross Profit -580K Operating Income -8.64M Net Income 4.8M EBITDA 7.87M EBIT 6.22M Earnings Per Share (EPS) 5.95
Full Income Statement Balance Sheet The company has 4.87M in cash and 20.56M in
debt, giving a net cash position of -15.69M.
Cash & Cash Equivalents 4.87M Total Debt 20.56M Net Cash -15.69M Retained Earnings -122.33M Total Assets 12.26M Working Capital 225K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -9.38M
and capital expenditures -637K, giving a free cash flow of -10.02M.
Operating Cash Flow -9.38M Capital Expenditures -637K Free Cash Flow -10.02M FCF Per Share n/a
Full Cash Flow Statement Margins Gross margin is -88.15%, with operating and profit margins of -1312.77% and 728.88%.
Gross Margin -88.15% Operating Margin -1312.77% Pretax Margin 728.88% Profit Margin 728.88% EBITDA Margin 1195.59% EBIT Margin -1312.77% FCF Margin -1522.64%
Dividends & Yields SCNI does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for SCNI.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 21, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date May 21, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -11.33 Piotroski F-Score 4
